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Background: We previously reported that IFN-γ producing 
T cell responses induced by the combined therapy of DNA 
vaccine and lamivudine for one year are important for the in-
duction of sustained virological response (SVR). However, 
IFN-γ production is not sufficient to predict sustained vir-
emia control in chronic hepatitis B (CHB) carriers treated. 
Methods: Twelve CHB carriers were intramuscularly immu-
nized 12 times at a 4-week interval with 8 mg of HBV DNA 
vaccine during the standard lamivudine treatment (100 
mg/daily/1 year). The level of cytokines during and after the 
combined therapy in plasma of all 12 CHB carriers treated 
was determined by each ELISA kit. Six out of 12 CHB car-
riers revisited the clinic, and their HBV DNA levels were 
examined. Results: The combined therapy increased plasma 
IL-12 and IL-12/p40 ratio during the treatment (baseline vs. 
peak level: 41.8±8.3 vs. 163.1±29.2 pg/ml; p＜0.01 and 
0.96±0.25 vs. 3.58±0.86; p＜0.01, respectively), and the 
peak level of plasma IL-12 and IL-12/p40 ratio was evoked at 
6 to 10 months during the combined therapy. In particular, 
CHB carriers with SVR had two and three-fold higher level of 
the peak plasma IL-12 and plasma IL-12/p40 ratio than 
non-virological responders (NVRs), respectively (218.0± 
41.4 vs. 108.1±28.6 pg/ml; p=0.09 and 5.35±1.38 vs. 
1.80±0.29; p＜0.05, respectively), while p40 level was con-
sistent during the combined therapy. In addition, there was 
no significant temporal correlation between the peak 
IL-12/p40 ratio and the elevation of serum alanine amino-
transferase (ALT) in this study, contrast to IFN-α therapy 
which induced peak IL-12 level following ALT flares. 
Conclusion: Our results indicate that the combined therapy 
induces the increase of plasma IL-12 and IL-12/p40 ratio, 
which are associated with long-term SVR in CHB carriers.
[Immune Network 2009;9(1):20-26]
INTRODUCTION
Two billion people have been infected with the hepatitis B 
virus (HBV) all over the world, and 400 million of them are 
estimated to be chronically infected (1). Despite effective pro-
phylactic vaccines, 50 million people are infected with HBV 
every year. About 80% of hepatocellular carcinoma (HCC) is 
caused by persistent chronic hepatitis B (CHB) infection. In 
addition, CHB carriers are highly susceptible to death by hep-
a t i c  c i r r h o s i s  a n d  H C C  ( 2 ) .
    We previously demonstrated that combined therapy of lam-
ivudine and DNA vaccine encoding all of the HBV antigens 
and  a  genetically  engineered  human  IL-12  mutant,  hIL-12 
N222L, induced a sustained virological response (SVR) for at 
least 1 year after the cessation of the combined therapy in 
six out of 12 CHB carriers, who are designated virological res-
ponders (VRs) (3). The other six carriers, the nonvirological 
responders (NVRs), had a high level of HBV DNA at the end 
of  the  combined  therapy  and  during  follow-up  periods.  In 
addition,  HBeAg  seroconversion  was  observed  during  the 
treatment in all 3 HBeAg-positive carriers with sustained viro-
l o g i c a l  r e s p o n s e s .  O n e  o f  t h e m  h a s  s h o w n  H B s A g  s e r o -
conversion at a follow-up period, which is hardly achievable 
by lamivudine monotherapy (4). Correspondingly, VRs showed Increase of IL-12/p40 Ratio by the Combined Therapy
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Figure 1. Experimental schedule of the pilot-clinical study. Lamivudine treatment for 8 weeks had been preceded before the first HB-100 injection
at T1 except for three subjects; V#118 at week 4, and V#105 and V#106 at week 12. The vaccinees were intramuscularly administrated 12 
times with 8 mg of HB-100 every 4 weeks as indicated by the arrows in combination with 100 mg of LAM treatment daily for 52 weeks (gray
rectangles) and another 52 weeks were followed (white rectangles). Plasma samples were obtained every 4 weeks (black circles) and the level 
of cytokines was evaluated by ELISA assay.
significantly  stronger  HBV-specific  Interferon(IFN)-γ  re-
sponses, mainly CD4
＋ memory T cell responses, than NVRs, 
both at the end of treatment and during follow-up periods. 
However, these HBV specific T cell responses are not statisti-
cally sufficient for predicting SVR, due to the small number 
of  CHB  carriers  recruited  in  this  study.
    It  is  well  documented  that  cytokines,  such  as  IFN-α/β, 
IFN-γ, tumor necrosis factor(TNF)-α, Interleukin(IL)-2, and 
IL-12, trigger viral clearance in many viral infections (5). In 
the case of HBV infection, the elimination of HBV was gen-
erally mediated by several cytokines such as IFN-α/β and 
IFN-γ via non-cytolytic mechanism (6). These cytokines con-
tribute to antiviral responses via the degradation of viral RNA 
by the increase of iNOS (7). In addition, the proteolytic cleav-
age of La autoantigen induced by theses cytokines also  in-
volves in the viral clearance by making viral RNA susceptible 
to host RNase (8). The previous report demonstrated that se-
rum IL-12 generated by IFN-α therapy is responsible for the 
viremia control in HBeAg-positive CHB carriers (9), indicating 
that the cytokines like IL-12 could have a significant role for 
the suppression of viral replication and would be an indicator 
to predict the sustained virological responses in CHB carriers. 
    In order to investigate a correlation between SVR and the 
level  of  cytokines  induced  by  the  combined  therapy  with 
DNA vaccine plus lamivudine, we analyzed the level of sev-
eral plasma cytokines by ELISA assay. Here, we demonstrated 
that significant increase of plasma IL-12 and IL-12/p40 ratio 
was transiently induced during the combined therapy. In ad-
dition, SVRs showed higher peak plasma IL-12/p40 ratio than 
NVRs,  indicating  a  potential  biomarker  to  predict  the  sus-
tained viremia control in the CHB carriers receiving chemo-
therapy  and  antigen-specific  immunotherapy. 
MATERIALS AND METHODS
Patients
W e  a s s e s s e d  p l a s m a  s a m p l e s  f r o m  1 2  C H B  c a r r i e r s  t r e a t e d  
with combined therapy of DNA vaccine plus lamivudine as 
previously  reported  (3).  Briefly,  represented  in  Fig.  1,  12 
Caucasian  CHB  carriers  were  enrolled  from  Ukraine  and 
Lithuania and injected 12 times with 8 mg of HB-100 express-
ing HBV S, pre S1/S2, core, polymerase, X protein and hu-
man IL-12 mutant (hIL-12N222L) intramuscularly at four-week 
interval in  combination with  100 mg of  lamivudine (Epivir- 
HBV,  GlaxoSmithKline)  daily  for  52  weeks.  Every  4  week, 
plasma samples were prepared and delivered to a central lab-
oratory at Pohang University of Science and Technology in 
Korea using a portable liquid nitrogen tank and subsequently 
used  for  ELISA  assay.  The  present  study  was  approved  by 
the  Pharmacological  Center  of  the  Ministry  of  Health  of 
Ukraine, by the Commission of Non-clinical and Clinical Trials 
of  the  State  Medicines  Control  Agency  of  the  Ministry  of 
Health  of  Lithuania.
    Six (V#103, V#106 and V#113; VRs and V#105, V#107 and 
V#114;  NVRs)  out  of  12  subjects  revisited  the  clinic  three 
years after the cessation of the combined therapy to inves-
tigate  their  long-term  virological  responses.
Cytokine ELISA
Plasma  samples  were  diluted  1:2  or  1:5  and  then  used  to 
measure  the  levels  of  cytokines  in  triplicate.  The  levels  of 
plasma  IL-12,  IL-2,  IFN-γ,  and  IL-4  were  determined  with Increase of IL-12/p40 Ratio by the Combined Therapy
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Figure 2. (A, B) Serial analysis of the average level of plasma IL-12, p40 (A), and IL-12/p40 ratio (B) (mean±SEM) in CHB carriers during and 
after the combined therapy of DNA vaccine plus lamivudine. The level of plasma IL-12 and p40 was determined by a specific ELISA. (*p＜0.05, 
**p＜0.01 by Wilcoxon signed rank test) (C-E) The level of plasma IL-12 (C), p40 (D), and IL-12/p40 ratio (E) in each subject was shown before 
the treatment (pre, T0), the peak level detected during the combined therapy (peak, usually T6 to T10), and at the end of treatment (end, T12).
specific ELISA kits according to the manufacturer’s protocols 
(IL-12, IL-2, and IL-4 : detection limit of 4 pg/ml, IFN-γ: de-
tection limit of 1 pg/ml, BD Biosciences). The levels of plas-
ma  p40  subunit  were  measured  using  a  specific  ELISA  kit 
with  2.7%  cross-reactivity  with  recombinant  IL-12  protein 
(detection  limit  of  32.1  pg/ml,  R&D  systems). 
Clinical laboratory tests
HBeAg,  HBsAg,  anti-HBe,  and  anti-HBs  antibodies  were 
measured with commercial enzyme immunoassay (EIA) kits 
(Monolisa, Biorad). Serum HBV DNA was measured using the 
Amplicor HBV monitor and Cobas Amplicor HBV monitor test 
(detection  limits  of  1,000  and  200  copies/ml,  respectively, 
Roche  Diagnostic  System),  and  then  data  were  represented 
as  average  values. 
Statistical analysis
Nonparametric  tests  such  as  the  Wilcoxon  signed  rank  test 
and Mann-Whitney U test were used for statistical analysis by 
applying  SAS  8.2  for  Windows  (SAS  Institute,  Cary,  North 
Carolina, USA) because the population of subjects was rela-
tively small and data did not meet parametric assumptions. 
The  Wilcoxon  signed  rank  test  was  used  to  evaluate  alter-
ations in levels of IL-12 and the IL-12/p40 ratio in each sub-
ject after combined therapy. Comparison of peak IL-12 levels, 
peak p40 levels and peak IL-12/p40 ratios between virological 
responders (VRs) and nonvirological responders (NVRs) was 
determined  by  the  Mann-Whitney  U  test. 
RESULTS
Combined therapy of DNA vaccine plus lamivudine 
led to IL-12 induction during the treatment
To investigate alterations of immunological characteristics as 
indicators to predict SVR by the combined therapy, the level 
of plasma IL-12, p40, IL-4, IL-2, and IFN-γ was monitored Increase of IL-12/p40 Ratio by the Combined Therapy
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Figure 3. The level of peak plasma IL-12, p40 (A), and peak IL-12/p40
ratio (B) between virological responders (VRs) and nonvirological 
responders (NVRs) after combined therapy. Peak plasma IL-12 and 
peak IL-12/p40 were mostly detected from 6 (T6) to 10 (T10) months
in 12 CHB carriers treated with combined therapy. The statistical 
analysis was done by Mann-Whitney U test.
longitudinally  in  each  individual  by  a  specific  ELISA  assay. 
Among  cytokines  analyzed,  only  IL-12  and  p40  were 
detectable.  The  highest  level  of  plasma  IL-12  (163.1±29.2 
pg/ml; mean±SEM) was observed 6 to 10 months after com-
bined therapy and was 4-fold higher than pretreatment level 
on the average (baseline vs. peak level; 41.8±8.3 pg/ml vs. 
163.1±29.2  pg/ml;  mean±SEM;  p＜0.01,  Wilcoxon  signed 
rank test) (Fig. 2A, C). However, it tended to return to basal 
levels  thereafter.  On  the  other  hand,  p40,  which  is  known 
as  a  natural  antagonist  against  IL-12,  was  not  significantly 
changed  regardless  of  the  treatment  except  one  patient 
( V # 1 1 2 )  ( F i g .  2 A ,  D ) .  S i m i l a r  t o  p l a s m a  I L - 1 2 ,  e l e v a t i o n  o f  
the  IL-12/p40  ratio  (3.58±0.86  from  0.96±0.25,  mean± 
SEM) was detected 6 to 10 months after combined therapy 
(p＜0.01, Wilcoxon signed rank test) (Fig. 2B, E). In an in-
dependent experiment, no significant change in plasma IL-12 
and  IL-12/p40  ratio  appeared  in  any  of  the  5  CHB  carriers 
treated  with  lamivudine  alone  (data  not  shown),  indicating 
that the increase of plasma IL-12 and IL-12/p40 ratio appears 
to be associated with DNA vaccine in combination with lam-
ivudine  treatment. 
VRs have significantly higher peak IL-12/p40 ratio 
than NVRs
When  the  peak  level  of  IL-12  was  compared  between  VRs 
and NVRs, VRs showed approximately a 2-fold higher level 
of peak plasma IL-12 than NVRs, albeit this was marginally 
significant (218.0±41.4 vs. 108.1±28.6 pg/ml, respectively; 
AVR±SEM; p=0.09, Mann-Whitney U) (Fig. 3A). Interestingly, 
VRs exhibited a significantly higher IL-12/p40 ratio than NVRs 
(5.35±1.38 vs. 1.80±0.29, respectively; AVR±SEM, p＜0.05 
Mann-Whitney U) (Fig. 3B). It is worth noting that there is 
n o  s i g n i f i c a n t  d i f f e r e n c e  i n  p r e t r e a t m e n t  l e v e l s  o f  p l a s m a  
IL-12 and IL-12/p40 ratios between VRs and NVRs. Our result 
is  so me h ow  si mi lar  to  t he  pr ev io u s re po rt s t h at  mu ri ne  re-
combinant IL-12 (rIL-12) can efficiently suppress HBV repli-
cation  in  transgenic  mice  (10)  and  that  the  recovery  from 
CHB by IFN-α treatment depends on the level of serum IL-12 
(9).  More  importantly,  human r I L - 1 2  p r o t e i n  a d m i n i s t e r e d  
subcutaneously inhibits viral replication in CHB patients with 
a peak serum level of IL-12 (173 pg/ml), which is similar to 
the peak IL-12 level (163.1 pg/ml) induced in this study (11). 
    In contrast to IFN-α therapy which induced hepatitis flares 
in 8 out of 10 VRs, followed by peak IL-12 level (9), the ele-
vation of alanine aminotransferase (ALT) level was generated 
in 2 out of 6 VRs during the treatment, and only one patient 
(V#118) showed concomitant elevation of ALT level with the 
increased IL-12/p40 ratio (Fig. 4), reflecting that there was no 
significant temporal correlation between the increase of plas-
ma IL-12 and an ALT flare in this study. These results indicate 
that our combined therapy could suppress viral replications 
presumably by the increased IL-12 without massive hepato-
cytolysis.
Virological responses are maintained in VRs for 3 
years after stopping combined therapy
Previously,  we  demonstrated  that  there  were  6  VRs  and  6 
NVRs,  as  determined  by  viral  loads  at  the  end  of  a  1-year 
follow-up.  Among  them,  six  subjects  (V#103,  V#106  and 
V#113;  VRs  and  V#105,  V#107  and  V#114;  NVRs)  have  re-
visited  the  clinic  3  years  after  the  cessation  of  combined 
therapy. When their serum viral loads were determined to ad-
dress  long-term  efficacy  of  combined  therapy,  two  (V#103, 
V#106) out of 3 VRs still showed undetectable serum viremia, 
and one subject (V#113) had a very low level of serum viral 
load (3,200 copies/ml), reflecting the maintained viremia con-
trol for up to 3 years in VRs after the combined therapy (Fig 
5). Interestingly, it is likely that all 3 VRs showed strong HBV 
antigen-specific  IFN-γ responses  or  higher  IL-12/p40  ratio 
(Table I), suggesting that they might be involved in controlled 
viremia in vaccinees. As expected, one subject (V#106) still 
maintained HBsAg seroconversion (data not shown). In con-
trast, all 3 NVRs had high viral loads 3 years after the cessa-Increase of IL-12/p40 Ratio by the Combined Therapy
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Figure 4. The longitudinal analysis of the
level of serum ATL and IL-12/p40 ratio
in virological responders during the 
combined therapy. The kinetics of serum
ALT levels (closed circles) and IL-12/p40
ratio (open circles) in VRs was compared 
in parallel to examine the temporal 
correlation between them.
Figure 5. The longitudinal analysis of serum viral loads for up to 3
years in CHB carriers treated with combined therapy. Three VRs 
(V#103, V#106 and V#113; closed circles) and 3 NVRs (V#105, 
V#107 and V#114; open circles) out of 12 subjects revisited the clinic
3 years after the stopping the combined therapy. Data were 
represented by the average serum viral loads according to the time 
point. (mean±SEM).
tion of combined therapy, even though two of them (V#105 
and V#107) had received IFN-α therapy for 6 months after 
the  follow-up  period,  and  their  serum  viral  loads  reached 
more than 200,000 and 162,000,000 copies/ml, respectively.
DISCUSSION
This experiment is the first finding to investigate plasma IL-12 
and  the  IL-12/p40  ratio  longitudinally  after  active  im-
munotherapy  such  as  DNA  vaccine  together  with  chemo-
t h e r a p y ,  w h i c h  c o r r e l a t e  w i t h  S V R  i n  C H B  c a r r i e r s  t r e a t e d .  
In  addition,  we  showed  that  long-term  therapeutic  efficacy 
had been sustained for at least 3 years after the cessation of 
the  combined  therapy. 
  L i k e  I F N - α therapy (9), combined therapy of DNA vaccine 
and lamivudine evoked an increase in peak IL-12 levels and 
peak  IL-12/p40  ratio  in  CHB  carriers  during  the  treatment. 
Different with IFN-α therapy, however, increase of plasma Increase of IL-12/p40 Ratio by the Combined Therapy
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Table I. The presence of HBeAg/anti-HBe, peak IL-12/p40 ratio, and HBV-specific T cell responses determined by ex vivo ELISPOT in 
each CHB carrier
Group Subjects
HBeAg/
anti-HBc status
Peak raio of
IL-12/p40
Env-specific
IFN-γ response
Core-specific
IFN-γ response
Pol-specific
IFN-γ response
Total
IFN-γ response
Virological
 responders
V#103
V#106
V#113
V#116
V#118
V#121
＋/−→−/＋
＋/−→−/＋
−/＋
＋/−→−/＋
−/＋
−/＋
1.45
2.21
6.84
6.76
10.5
4.3
360
505
335
175
115
540
440
410
405
285
200
610
365
490
430
305
185
690
1,165
1,405
1,170
   765
   500
1,840
Non-virological
 responders
V#105
V#107
V#109
V#110
V#112
V#114
＋/−
＋/−
−/＋
−/＋
−/＋
＋/−
1.18
2.21
1.82
0.78
2.15
2.38
50
65
10
160
180
100
170
75
20
125
240
285
80
70
15
140
245
385
300
210
45
425
665
770
HBV antigen-specific IFN-γ  response reflects the number of spots per 10
6 PBMCs determined by IFN-γ  ELISPOT assay excluding that
generated by HCV E2 peptide.
IL-12 and IL-12/p40 ratio did not correlate directly with the 
elevation of ALT levels in this study. This discrepancy could 
be explained as follows: It is possible that major cell types 
secreting IL-12 are different between IFN-α therapy and our 
combined  therapy.  IFN-α treatment  leads  to  systemic  im-
mune stimulation and hepatocellular necrosis, recruiting mac-
rophages and noncommitted T cells into the liver (9). In con-
trast, after the combined therapy, IL-12 could be mainly se-
creted by activated dendritic cells stimulated by DNA vacci-
nation under lamivudine treatment in the secondary lymphoid 
organs,  not  in  the  liver,  resulting  in  generation  of  anti-
gen-specific type I T helper responses. Such Th1 responses 
represented by secretion of IFN-γ and other Th1 cytokines 
resulted  in  viral  suppression  via  non-cytolytic  mechanisms 
(12), such as elimination of HBV nucleocapsid particles and 
destabilization of the viral RNA. In addition, it is likely that 
ALT flares occur in proportion to the level of serum/plasma 
IL-12. The concentration of plasma IL-12 detected after our 
combined  therapy  reaches  several  hundred  pg/ml.  On  the 
other hand, IFN-α therapy induced more than 10 ng/ml of 
p e a k  s e r u m  I L - 1 2 ,  w h i c h  m e d i a t e d  e x c e s s i v e  i n f l a m m a t i o n  
and  destruction  of  hepatocytes  (9).
    It is arguable that the observed plasma IL-12 may be de-
rived from the injected plasmid encoding hIL-12 mutant in-
cluded  in  our  DNA  vaccine  or  not.  However,  the  plasma 
IL-12 is likely to be synthesized by the host immune system 
stimulated by the DNA vaccine on the basis of the following 
observations: DNA vaccine was administered twelve times at 
a 4-week interval, but plasma IL-12 was induced only from 
T4  to  T10  in  the  vaccinees,  and  disappeared  thereafter.  In 
addition, it was previously reported that gene expression of 
the injected DNA reached its peak level on days 1∼3, and 
then declined to the basal level after 2 weeks in the muscle 
(13).  Similarly,  when  mice  were  injected  with  100μg  of 
hIL-12N222L (＞100X of human dose as calculated with body 
weight),  low  levels  of  peak  human  IL-12  (25±3.2  pg/ml, 
mean±SEM) were observed only in the muscle on the second 
day after injection, but was not detected in plasma and serum 
during the month (our unpublished data), possibly excluding 
the  produ ction  of plasm a I L-12  from  in jec te d plasm id itself.
    Although both IL-12 and IFN-γ production are considered as 
Th1 responses, two patients (V#116, V#118) had weak IFN-γ 
responses even though they showed higher IL-12/p40 ratio. 
It is likely that the discrepancy between IFN-γ responses and 
IL-12/p40 ratio relied on the time point analyzed, that is, peak 
IL-12/p40 ratio was generated at T6 to T10 in most cases but 
IFN-γ responses were determined at only T12 or F1. To clar-
ify  the  correlation  between  IL-12/p40  ratio  and  IFN-γ re-
sponses, the longitudinal analysis of IFN-γ responses during 
the treatment should be performed for a next clinical study.
  Because there was no significant correlation between IL-12 
induction and IFN-γ responses in each individual, the IL-12 Increase of IL-12/p40 Ratio by the Combined Therapy
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induction could be regarded as an independent parameter to 
effect on the SVR in CHB carriers treated with the combined 
therapy (Table I). In addition, according to our previous and 
present study, one parameter such as IFN-γ production or 
IL-12/p40 ratio alone is not sufficient to predict SVR in CHB 
carriers treated although NVRs showed both weak IFN-γ re-
sponses and low IL-12/p40 ratio. Combined both parameters, 
we  suggested  that  “the  level  of  the  plasma  IL-12/p40  ratio 
or  the  number  of  env-specific  IFN-γ secreting  cells/10
6 
PBMCs as determined by ex-vivo ELISPOT assay” c o ul d b e 
u s e d  a s  a n  e a r l y  b i o m a r k e r  a l t e r n a t i v e l y  t o  p r e d i c t  a  
long-term SVR after stopping the combined therapy. All NVRs 
had fewer than 200 env-specific IFN-γ secreting cells per 10
6 
PBMCs and less than 3 of peak IL-12/p40 ratio (0.79∼2.67, 
1.8±0.3;  mean±SEM).  In  contrast,  all  VRs  showed  more 
than  300  env-specific  IFN-γ secreting cells per 10
6 PB M Cs 
or more than 4 of peak IL-12/p40 ratio (Table I). Taken to-
gether,  it  is  possible  to  suggest  that  vaccinees  showing＞4 
peak IL-12/p40 ratio or ＞300 env-specific IFN-γ secreting 
cells/10
6 P B M C s  b y  ex  vivo  ELISPOT  assay  could  suppress 
HBV replication for a long time after stopping the combined 
therapy, indicating the possibility as novel early biomarkers. 
However, since we analyzed the small number of CHB car-
ri er s,  o ur  ob se rv at io n s re q ui re  fu rt he r v al id at io n i n a  lar g er 
cohort  of  CHB  carriers  treated  with  the  combined  therapy.
    In  conclusion,  our  study  suggests  that  combined  therapy 
of  DNA  vaccine  and  lamivudine  leads  to  the  induction  of 
plasma IL-12 and IL-12/p40 ratio. In addition, the elevation 
of plasma IL-12/p40 ratio as well as HBV-specific IFN-γ re-
sponses is closely associated with the viremia control in CHB 
carriers, and could be used for early biomarkers to predict 
the  SVR  after  the  cessation  of  the  combined  therapy. 
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